Clinical trials: irinotecan hydrochloride
Solid Tumor
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
The purpose of this research study is to test the safety and of adding bevacizumab to the established regimen of vincristine, oral irinotecan, and temozolomide (VOIT) and see what effects it has in pediatric patients with…
- Trial name
- VITAC (NCT00786669)
- Testing
- Bevacizumab, Temozolomide, Vincristine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Mucinous Ovarian Cancer, Fallopian Tube Cancer
Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma
This research study is evaluating a modified FOLFIRINOX plus bevacizumab therapy for mucinous ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
- Conditions
- Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05665023
- Testing
- Bevacizumab + modified FOLFIRINOX
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Yonsei University
Metastatic Colon Cancer, Stage III Colon Cancer
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer.
- Trial name
- NCT03803553
- Testing
- FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Adenocarcinoma
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
The purpose of this Phase 1b study is to investigate whether intravenous administration of REOLYSIN® in combination with chemotherapy and pembrolizumab is effective and safe in the treatment of pancreatic adenocarcinoma.
- Trial name
- NCT02620423
- Testing
- REOLYSIN®, Chemotherapy, Gemcitabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Oncolytics Biotech
Unspecified Childhood Solid Tumor, Protocol Specific
Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children with refractory or…
- Trial name
- NCT00008424
- Testing
- irinotecan hydrochloride
- Where
- 51 sites in United States, Australia and 1 more
- Volunteers
- 7 people
- Sponsor
- Children's Oncology Group
Sarcoma
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
Refractory soft tissue sarcoma remains a difficult malignancy to treat. The mammalian target of rapamycin (mTOR) is an enzyme that plays an important role in cancer cell survival.
- Trial name
- NCT00996346
- Testing
- Irinotecan&Temsirolimus:Arm1, Level 1, Irinotecan&Temsirolimus:Arm 1, Level 2, Irinotecan&Temsirolimus:Arm 2, Level 1
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- New Mexico Cancer Research Alliance
Glioblastoma, Rhabdomyosarcomas
ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
The purpose of this Phase I study is to find the largest dose of the drug irinotecan, in combination with ZD1839, that can be given safely to children and to learn the good and bad effects.
- Conditions
- Glioblastoma, Rhabdomyosarcomas, Neuroblastoma, Osteosarcoma
- Trial name
- NCT00132158
- Testing
- Irinotecan (Camptosar), Gefitinib (Iressa)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- St. Jude Children's Research Hospital
Locally Advanced Rectal Cancer (LARC)
A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer
This is an exploratory, open-label, single arm, non-randomized, multicenter, phase II clinical trial to determine the efficacy and clinical complete response rate in patients with rectal cancer and tumor preoperative evaluation…
- Trial name
- NCT04009876
- Testing
- nal-IRI, Surgical resection, Watch-and-wait
- Where
- 4 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundación de investigación HM
Colorectal Cancer
Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC
This phase III study will compare two combinations of irinotecan, Folfiri versus Xeliri, with the addition of Avastin as 1st line treatment of colorectal cancer.
- Trial name
- NCT00469443
- Testing
- Irinotecan, 5-Fluorouracil, Leucovorin
- Where
- 8 sites in Greece
- Volunteers
- 330 people
- Sponsor
- Hellenic Oncology Research Group
Colorectal Adenocarcinoma, RAS Wild Type
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well irinotecan and cetuximab with or without bevacizumab work in treating patients with RAS wild-type colorectal cancer that has spread to other places in the body (locally…
- Conditions
- Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7
- Trial name
- NCT02292758
- Testing
- Bevacizumab, Cetuximab, Irinotecan
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Academic and Community Cancer Research United
Colorectal Cancer
Prevention of Irinotecan Induced Diarrhea by Probiotics
Irinotecan is one of key drug used in the treatment of colorectal cancer. The incidence of irinotecan induced diarrhea varies between 60-90%, with severe diarrhea in 20-40%.
- Trial name
- NCT01410955
- Testing
- Probiotic formula
- Where
- 6 sites in Slovakia
- Volunteers
- 46 people
- Sponsor
- Monsea Ltd.
Metastatic Colorectal Cancer, CRC
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in…
- Conditions
- Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
- Trial name
- NCT06106308
- Testing
- Onvansertib, FOLFIRI, Bevacizumab
- Where
- 41 sites in United States
- Volunteers
- 110 people
- Sponsor
- Cardiff Oncology
Metastatic Colorectal Cancer
Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients
Aim of the present study is to investigate whether baseline or early post-treatment (one month after treatment commencement) frequency of peripheral T regulatory lymphocytes (Tregs OR CD4+/CD25high/FOXP3+ T cells), known to…
- Trial name
- NCT01533740
- Testing
- fluorouracil/irinotecan/levo-folinic acid/bevacizumab
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- University of Rome Tor Vergata
Colorectal Neoplasms, Intestinal Neoplasms
Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
Bevacizumab, as an antibody of vascular endothelial generated factor (VEGF), combined with the fluorouracil-based chemotherapy regimens for metastatic colorectal cancer, has become the classical first-line treatment.
- Conditions
- Colorectal Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms
- Trial name
- NCT03271255
- Testing
- Apatinib Mesylate Tablets, Bevacizumab Injection
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shenzhen People's Hospital
Metastatic Colorectal Cancer
Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project
Molecular imaging with positron emission tomography (PET) using [18F] fluorodeoxyglucose (FDG) has been suggested as an early, sensitive marker of tumour response to anticancer drugs by monitoring the changes in glucose…
- Trial name
- NCT00828620
- Testing
- Imaging study
- Where
- 6 sites in Belgium
- Volunteers
- 21 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Metastatic Colorectal Cancer
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or…
- Trial name
- CodeBreaK 301 (NCT06252649)
- Testing
- FOLFIRI Regimen, Sotorasib, Panitumumab
- Where
- 291 sites in United States, Argentina and 33 more
- Volunteers
- 450 people
- Sponsor
- Amgen
Metastatic Pancreatic Adenocarcinoma
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
This study will be looking at whether gemcitabine, taxotere, and xeloda (GTX) in combination with cisplatin and irinotecan is effective (anti-tumor activity) and safe in patients with metastatic pancreatic cancer.
- Trial name
- NCT02324543
- Testing
- Gemcitabine, Taxotere, Xeloda
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer, Peritoneal Metastases
Efficacy of Hyperthermic Intraperitoneal Chemotherapy
A dose titration study and a combined superiority registry-based open-label randomized control trial is planned to answer the trial objectives. The study will be registry-based to allow simpler and more comprehensive follow-up.
- Trial name
- EFFIPEC (NCT04861558)
- Testing
- 5Fluorouracil, Irinotecan, Oxaliplatin
- Where
- 5 sites in India, Sweden
- Volunteers
- 213 people
- Sponsor
- Uppsala University
Glioblastoma, Optic Neuropathy
Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab
Does treatment with bevacizumab (Avastin) in combination with prior or current radiotherapy lead to optic neuropathy?
- Trial name
- NCT01331616
- Testing
- Bevacizumab (Avastin)
- Sponsor
- West Penn Allegheny Health System
Gastrointestinal Cancer, Metastatic
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
This study is open to adults with advanced colorectal cancer or with advanced pancreatic cancer. The study has 2 parts. In the first part, participants with colorectal cancer get a medicine called BI 905711 combined with…
- Trial name
- NCT05087992
- Testing
- BI 905711, FOLFIRI, Bevacizumab
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 13 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.